ipilimumab
bms
['melanoma', 'ipilimumab', 'rafael ']
tumor infiltrating lymphocyte vs. ipilimumab, in metastatic melanoma after anti-pd1 failure. response rate of 49% vs. 20% and median overall survival of 25.8 vs 18.9 months. an old therapy fully established as an alternative. #esmo22
Oncologista Clínico em São Paulo dedicado às áreas de Melanoma e Sarcoma. Medical Oncologist in São Paulo, Brazil, dedicated to Melanoma and Sarcoma fields.